CARDIOVASCULAR RISK FACTOR MANAGEMENT: SINGLE-PILL AMLODIPINE/ATORVASTATIN VERSUS USUAL CARE IN PATIENTS WITH HYPERTENSION AND ADDITIONAL RISK FACTORS - THE CRUCIAL TRIAL: PP.16.96